On the Immuno -oncology space an article here about an American...

On the Immuno -oncology space an article here about an American company Janux developing novel solid tumor therapies,
it's therapies sound very similar to IMU CF33-CD 19 a mark and kill approach targeting proteins on tumor cells, but not CD19

it's shares tripled overnight when a licensing deal was announced company value jumped to $2B US. It was reported Investors liked the safety profile of it's drug over that of others in the same space.

My take is exactly what Lesley says data data data, safety, efficacy, = Rocketship

Interesting read for some enjoy

Janux shares triple on early cancer immunotherapy data | BioPharma Dive